Fusion Pharmaceuticals Inc.
FUSNDelisted Jun 5, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001805890
Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Fusion Pharmaceuticals Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
FUSN is no longer listed, and 13F filings after Q1 2024 list far fewer holders. See Q1 2024
- Institutional holders
- 0
- −112 vs. Q1 2024
- Shares held
- 0
- −69.0M (−100.0%) vs. Q1 2024
- Total value
- $0
- −$1.47B (−100.0%) vs. Q1 2024
- New holders
- 0
- 0 more added
- Sold out
- 112
- 0 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FUSN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 114 | $1.47B |
| Q4 2023 | 77 | $584.1M |
| Q3 2023 | 41 | $129.8M |
| Q2 2023 | 41 | $235.1M |
| Q1 2023 | 38 | $171.9M |
| Q4 2022 | 30 | $88.9M |
| Q3 2022 | 34 | $80.3M |
| Q2 2022 | 31 | $69.4M |
| Q1 2022 | 28 | $219.1M |
| Q4 2021 | 32 | $116.0M |
| Q3 2021 | 40 | $220.6M |
| Q2 2021 | 39 | $221.8M |
| Q1 2021 | 38 | $295.9M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Fusion Pharmaceuticals Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −5,252−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −2,949−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −924−100.0% | Sold out |
| TD Waterhouse Canada Inc. | 0 | $0 | 0.00% | −700−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −508−100.0% | Sold out |
| Toth Financial Advisory Corp | 0 | $0 | 0.00% | −501−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −349−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −268−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Scarborough Advisors, LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |
| Cutler Group LP | – | – | – | – | Not filed |